content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Asterias Biotherapeutics (AST)

3.35
0.10
(3.08%)
Sep 11, 4:00PM EDT
content_middle

Asterias Biotherapeutics (NYSEMKT: AST), a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine.

AST develops therapeutic products in the areas of neurology and oncology.

Its clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke.  AST also develops immunotherapeutic programs, such as AST-VAC1, an autologous product candidate that has completed a Phase II clinical trial for the treatment of acute myelogenous leukemia; and AST-VAC2, which is in a Phase I/IIa clinical trial, an allogeneic and cancer vaccine candidate designed to stimulate patient immune responses to telomerase.

Asterias Biotherapeutics was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.

Previous Close: 
3.25
Open: 
3.20
Bid: 
2.95
Ask: 
3.85
1yr Target Price: 
10.15
Day's Range: 
3.20 - 3.35
52wk Range: 
2.83 - 5.80
Volume: 
160265
Average Daily Volume: 
111902
Market Capitalization: 
167.43M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
49978000M
content_right

Pages